0000880771-17-000091.txt : 20170606
0000880771-17-000091.hdr.sgml : 20170606
20170606183741
ACCESSION NUMBER: 0000880771-17-000091
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170602
FILED AS OF DATE: 20170606
DATE AS OF CHANGE: 20170606
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Blobel Friedhelm
CENTRAL INDEX KEY: 0001363213
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 17895262
MAIL ADDRESS:
STREET 1: 950 TOWER LANE, SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
certent-form4.xml
PRIMARY DOCUMENT
X0306
4
2017-06-02
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001363213
Blobel Friedhelm
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
1
1
0
0
President & CEO
Common Stock
2017-06-02
4
M
0
4800
3.55
A
98099
D
Common Stock
2017-06-02
4
S
0
4800
10
D
93299
D
Common Stock
2017-06-06
4
M
0
5500
3.55
A
98799
D
Common Stock
2017-06-06
4
S
0
5500
10.00
D
93299
D
Non-Qualified Stock Option (right to buy)
3.55
2017-06-02
4
M
0
4800
0
D
2020-03-05
Common Stock
4800
142810
D
Non-Qualified Stock Option (right to buy)
3.55
2017-06-06
4
M
0
5500
0
D
2020-03-05
Common Stock
5500
137310
D
The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
Includes 773 shares purchased under the Issuer's Employee Purchase Plan on May 31, 2017.
Granted under the Issuer's 2005 Equity Incentive Plan.
25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.
/s/ Friedhelm Blobel, Ph.D.
2017-06-06